Please login to the form below
OncoVex
This page shows the latest OncoVex news and features for those working in and with pharma, biotech and healthcare.
AZ signs yet another cancer immunotherapy deal
The most advanced is Amgen's OncoVex (talimogene laherparepvec), which in 2013 became the first oncolytic virus to show efficacy in a phase III trial involving people with the skin cancer
Latest news
-
Amgen says viral melanoma therapy clears phase III trial
OncoVex demonstrates durable response in skin cancer patients. A novel therapy for skin cancer which makes use of the cell-killing activity of a virus has shown efficacy in a phase ... The melanoma immunotherapeutic - talimogene laherparepvec (also known
-
Disease focus: Melanoma
nilotinib. In development. Vaccines. OncoVEX GM-CSF. In development. Vaccines. MAGE-A3 ASCI.
-
Amgen to buy BioVex
BioVex's portfolio includes OncoVex (GM-CSF) – an investigational vaccine to treat melanoma and head and neck cancer. ... Philip Astley-Sparke, CEO, BioVex, also praised the agreement: "Amgen is ideally positioned to leverage the potential of OncoVEX
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Featured jobs
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Account Director, Healthcare Communications
-
Salary TBC
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Account Director – UK Office
-
Excellent salary and benefits
Subscribe to our email news alerts
- GSK hires Merck KGaA exec to lead US pharma business
- Novartis chooses internal replacement for US pharma president role
- Moving annual total (MAT)
- Roche undercuts price of Bayer cancer drug after winning FDA approval
- Novartis chooses internal replacement for US pharma president role
- Lilly psoriasis drug beats J&J's Tremfya in head-to-head trial
- A uniquely English genomic medicine service
- FDA rejects Sarepta’s new Duchenne drug over safety fears
- AZ claims first-in-class win for Farxiga in heart failure
- UK no longer measles-free as vaccination rates fall dramatically
- Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO
- Blended Intelligence
PMHub
Market Access Transformation
Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...
Latest intelligence
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
- The relevance of patient perspectives to value
- Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
Quick links
Infographics
